Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia

References

• Sallan SE. Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. In: Hematology am soc hematol educ program. 2006:128–132.
   Google Scholar
• Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98(11):1702–1710.
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–1411.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Gondos A, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014;9(1):e85554.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–1669.
   Google Scholar
• Mullighan CG. Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(4):314–324.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood. 2005;106(4):1189–1198.
   PubMed Web of Science ®Google Scholar
• Mullighan CG. The genomic landscape of acute lymphoblastic leukemia in children and young adults. Hematology Am Soc Hematol Educ Program. 2014;2014(1):174–180.
   PubMedGoogle Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Propp S, Lizzi FA. Philadelphia chromosome in acute lymphocytic leukemia. Blood. 1970;36(3):353–360.
   PubMed Web of Science ®Google Scholar
• Burmeister T, Schwartz S, Bartram CR, et al. Patients’ age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112(3):918–919.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–178.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). In: Hematology Am Soc Hematol Educ Program. 2009:371–381.
   Google Scholar
• Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342(14):998–1006.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547–561.
   PubMed Web of Science ®Google Scholar
• Gleer B, Gökbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German multicenter trial group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536–1543.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia–results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357–2366.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–2801.
   PubMed Web of Science ®Google Scholar
• Avivi I, Goldstone AH. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant. 2003;31(8):623–632.
   PubMed Web of Science ®Google Scholar
• Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112(3):903–909.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489–4496.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL–Positive acute lymphoblastic leukemia: a Phase II study by the Japan adult leukemia study group. J Clin Oncol. 2006;24(3):460–466.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–2541.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676–3678.
   Web of Science ®Google Scholar
• Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2009;145(5):581–597.
   PubMed Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644–3652.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Li X, Gentleman R, et al., Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res. 2005;11(20):7209–7219.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al., Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–480.
   PubMed Web of Science ®Google Scholar
• Den Boer ML, van Slegtenhorst M, De Menezes RX, et al., A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2): 125–134.
   PubMed Web of Science ®Google Scholar
• Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312–5321.
   PubMed Web of Science ®Google Scholar
• van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622–2629.
   PubMed Web of Science ®Google Scholar
• Ofran Y, Izraeli S. BCR-ABL (Ph)-like acute leukemia-pathogenesis, diagnosis and therapeutic options. Blood Rev. 2017;31(2):11–16.
   PubMed Web of Science ®Google Scholar
• Herold T, Schneider S, Metzeler KH, et al. Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2017;102(1):130–138.
   PubMed Web of Science ®Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510–3518.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Li Y, Payne-Turner D, et al., Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–1015.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2017;129(2):177–187.
   PubMed Web of Science ®Google Scholar
• Heatley SL, Sadras T, Kok CH, et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica. 2017;102(12):e490–e493.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Messina M, Della Starza I, et al. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica. 2020;106(6):1559–1568.
   Web of Science ®Google Scholar
• Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1–Like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27):3012–3020.
   PubMed Web of Science ®Google Scholar
• Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2017;18(9):1904.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396–4407.
   PubMed Web of Science ®Google Scholar
• Towatari M, Yanada M, Usui N, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104(12):3507–3512.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108(5):1469–1477.
   PubMed Web of Science ®Google Scholar
• de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408–1413.
   PubMed Web of Science ®Google Scholar
• Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19(1):150–155.
   PubMed Web of Science ®Google Scholar
• Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653–661.
   Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–850.
   PubMed Web of Science ®Google Scholar
• Ribera JM, García O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol. 2012;159(1):78–81.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al., Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24): 3711–3719.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer. 2007;109(10):2068–2076.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Vitale A, Vignetti M, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101(12):1544–1552.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Saha V, Devidas M, et al. CA180-372: an international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2017;130(Suppl_1):98.
   PubMedGoogle Scholar
• Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children’s oncology group trial AALL0622. J Clin Oncol. 2018;36(22):2306–2314.
   PubMed Web of Science ®Google Scholar
• Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31(4):589–612.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Lange T, Wystub S, et al. Prevalence and dynamics of BCR-ABL kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent BCR-ABL positive acute lymphoblastic leukemia. Leukemia. 2012;26(7):1475–1481.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110(7):2309–2315.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–2551.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1411–1413.
   PubMed Web of Science ®Google Scholar
• Sekimizu M, Yamashita Y, Ueki H, et al. Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib. Leuk Lymphoma. 2014;55(7):1652–1653.
   PubMed Web of Science ®Google Scholar
• Farnsworth P, Ward D, Reddy V. Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation. Exp Hematol Oncol. 2012;1(1):29.
   PubMedGoogle Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–1796.
   PubMed Web of Science ®Google Scholar
• Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother. 2013;47(11):1540–1546.
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian H, Pui CH, et al. SOHO state of the art update and next questions: philadelphia chromosome–positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(7):439–446.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070–2077.
   Google Scholar
• Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158–4164.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774–782.
   PubMed Web of Science ®Google Scholar
• Foà R, Vitale A, Vignetti M, et al., Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–6528. .
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Ansuinelli M, Vitale A, et al. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica. 2021;106(7):1828–1838.
   Web of Science ®Google Scholar
• Foà R, Bassan R, Vitale A, et al., Dasatinib-blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Bassan R, Vitale A, et al. Updated results of the GIMEMA LAL2116, D-ALBA trial, for newly diagnosed adults with Ph+ ALL. HemaSphere. 2021;5(S2):7.
   Google Scholar
• Shen S, Chen X, Cai J, et al. Effect of Dasatinib vs Imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358–366.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002–1009.
   Web of Science ®Google Scholar
• Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–756.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Rousselot P, Cayuela JM, et al. Nilotinib combined with lower-intensity chemotherapy for front-line treatment of younger adults with ph positive acute lymphoblastic leukemia (ALL): interim analysis of the GRAAPH-2014 trial. HemaSphere. 2018;2(S1):410‐411.
   Google Scholar
• Liu B, Wang Y, Zhou C, et al. Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up. Ann Hematol. 2019;98(3):633–645.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Papayannidis C, Piciocchi A, et al. Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408. Cancer Res. 2014;74(19 Suppl):5552.
   Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al., Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15): 1547–1555.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618–e627.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650–3656.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Piciocchi A, Papayannidis C, et al. First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017;130(Suppl_1):99.
   Google Scholar
• Ribera JM, García O, Martinez P, et al. Ponatinib and chemotherapy in young adults with de novo Philadelphia chromosome-positive acute lymphoblstic leukemia. Preliminary results of Ponalfil clinical trial. Blood. 2019;134(Suppl_1):3874.
   Google Scholar
• Short NJ, Kantarjian HM, Konopleva M, et al. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: early results from a phase II study. J Clin Oncol. 2021;39(15 suppl):7001.
   Google Scholar
• Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021;96(8):1000–1007.
   Web of Science ®Google Scholar
• Tavitian S, Uzunov M, Bérard E, et al. Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study. Leuk Lymphoma. 2020;61(9):2161–2167.
   PubMed Web of Science ®Google Scholar
• Couturier MA, Thomas X, Raffoux E, et al. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma. 2021;62(3):620–629.
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562–2569.
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahi SK, et al., BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3): 428–442.
   PubMed Web of Science ®Google Scholar
• Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733–737.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–2326.
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120–8135.
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highy resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431–443.
   PubMed Web of Science ®Google Scholar
• Pemovska T, Johnson E, Kontro M, et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015 Mar 5;519(7541):102–105.
   PubMed Web of Science ®Google Scholar
• Giudice V. Ghelli Luserna di Rorà A, et al. Axitinib in ponatinib-resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation. Int J Mol Sci. 2020;21(24):9724.
   Web of Science ®Google Scholar
• Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;100(7):898–904.
   Web of Science ®Google Scholar
• Roberts KG, Gu Z, Payne-Turner D, et al., High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Messina M, Foà R. BCR/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat? Cancer. 2019;125(2):194–204.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Steinherz PG, Sather HN Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2008; 111(5):2548–2555.
   Google Scholar
• Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv. 2020;4(1):218–228.
   PubMed Web of Science ®Google Scholar
• Fasan A, Kern W, Nadarajah N, et al. Three steps to the diagnosis of adult Ph-like ALL. Blood. 2015;126(23):2610.
   Web of Science ®Google Scholar
• Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group. Blood. 2017;129(25):3352–3361.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Messina M, Grammatico S, et al. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. Br J Haematol. 2018;181(5):642–652.
   PubMed Web of Science ®Google Scholar
• Rahman ZA, Heckman M, Anagnostou T, et al. Adult Philadelphia-like B-cell acute lymphoblastic leukemia: characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia. J Clin Oncol. 2021;39(15 suppl):7022.
   Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–1559.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Hurtz C, Wertheim GB, et al. High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL. Leukemia. 2017;31(4):981–984.
   PubMed Web of Science ®Google Scholar
• Maese L, Raetz EA. Can Ph-like ALL be effectively targeted? Best Pract Res Clin Haematol. 2019;32(4):101096.
   PubMed Web of Science ®Google Scholar
• Perwein T, Strehl S, Konig M. Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2016;101(8):e332–e335.
   PubMed Web of Science ®Google Scholar
• Frech M, Jehn LB, Stabla K. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2017;2(4):e160–e162.
   Google Scholar
• Frisch A, Ofran Y. How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica. 2019;104(11):2135–2143.
   PubMed Web of Science ®Google Scholar
• Jain N, Jabbour EJ, McKay PZ, et al. Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I-II trial. Blood. 2017;130(Suppl_1):1322.
   Google Scholar
• Collette Y, Prébet T, Goubard A, et al. Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer J. 2015;5(3):e292.
   PubMed Web of Science ®Google Scholar
• Lunghi M, Patriarca A, Greco M, et al. Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. Leuk Lymphoma. 2021;62(3):755–757.
   PubMed Web of Science ®Google Scholar
• Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019;134(16):1351–1355.
   PubMed Web of Science ®Google Scholar
• Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the in vitro and in vivo efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated acute lymphoblastic leukemia. Mol Cancer Ther. 2015;14(2):364–374.
   PubMed Web of Science ®Google Scholar
• Kim SK, Knight DA, Jones LR, et al. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Genes Dev. 2018;32(11–12):849–864.
   PubMed Web of Science ®Google Scholar
• Loh ML, Tasian SK, Rabin KR, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a children’s oncology group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62(10):1717–1724.
   PubMed Web of Science ®Google Scholar
• Barba P, Morgades M, Montesinos P, et al. Increased survival due to lower toxicity for high‐risk T‐cell acute lymphoblastic leukemia patients in two consecutive pediatric‐inspired PETHEMA trials. Eur J Haematol. 2019;102(1):79‐86.
   PubMed Web of Science ®Google Scholar
• Testi AM, Canichella M, Vitale A, et al. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. Am J Hematol. 2021;96(3):292–301.
   Web of Science ®Google Scholar
• Burmeister T, Gökbuget N, Reinhardt R, et al. NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood. 2006;108(10):3556–3559.
   PubMed Web of Science ®Google Scholar
• Messina M, Chiaretti S, Tavolaro S, et al. Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia. Cancer. 2010;116(14):3426–3437.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Tavolaro S, Ghia EM, et al. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica. 2007;92(5):619–626.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Tong W, Manshouri T, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008;22(6):1117–1124.
   PubMed Web of Science ®Google Scholar
• De Keersmaecker K, Versele M, Cools J, et al. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia. 2008;22(12):2208.
   PubMed Web of Science ®Google Scholar
• Zaliova M, Moorman AV, Cazzaniga G, et al. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica. 2016;101(9):1082–1093.
   PubMed Web of Science ®Google Scholar
• Vicente C, Schwab C, Broux M, et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica. 2015;100(10):1301–1310.
   PubMed Web of Science ®Google Scholar
• Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205(4):751–758.
   PubMed Web of Science ®Google Scholar
• Degryse S, Cools J. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia. J Hematol Oncol. 2015;8(1):91.
   PubMedGoogle Scholar
• La Starza R, Messina M, Gianfelici V, et al. High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. Leukemia. 2018;32(8):1807–1810.
   PubMed Web of Science ®Google Scholar
• Garcia PD, Langowski JL, Wang Y, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014;20(7):1834–1845.
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392–399.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Foà R. Management of adult Ph-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):406–413.
   PubMedGoogle Scholar
• Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111–115.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Potter M, et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: an analysis by the acute leukemia working party of the EBMT. Eur J Cancer. 2018;96:73–81.
   PubMed Web of Science ®Google Scholar
• Capria S, Pepe S, Trisolini SM, et al. Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease. Leuk Lymphoma. 2019;60(1):274–276.
   PubMed Web of Science ®Google Scholar
• Gaur S, Torabi AR, Corral J. Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor. Vivo. 2014;28(6):1149–1153.
   Web of Science ®Google Scholar
• Abid MB, De Mel S. Does ponatinib cross the blood-brain barrier? Br J Haematol. 2017;179(3):497–498.
   PubMed Web of Science ®Google Scholar